Introduction
============

COPD is a common, preventable, and treatable chronic respiratory disease characterized by persistent respiratory symptoms and airflow limitation. It has become one of the leading causes of death worldwide, posing a heavy burden on economy and society.[@b1-copd-13-3011] Many attempts have been made to find simple and effective indicators to assess the severity of the disease. Prior to 2011, the severity of COPD was mainly evaluated by lung function, namely FEV~1~. However, COPD has obvious heterogeneity in many aspects, such as clinical manifestations, pathophysiology, drug efficacy, survival, and prognosis. Therefore, FEV~1~ alone cannot fully reflect the characteristics of the disease.[@b2-copd-13-3011],[@b3-copd-13-3011] The 2011 Global Initiative for Chronic Obstructive Lung Disease (GOLD) proposed the A-B-C-D assessment approach, which evaluates COPD based on symptoms, airflow limitation, and history of exacerbations, and reflects the complexity of the disease in a more effective manner.[@b4-copd-13-3011] However, several studies have shown this staging system has no significant advantage in predicting mortality and significant health outcomes compared with traditional one-dimensional assessment systems, and may cause some confusion.[@b5-copd-13-3011]--[@b8-copd-13-3011]

In view of these limitations, the 2017 revision separates the degree of airflow limitation from the A-B-C-D grouping, emphasizing the importance of the symptoms and the risk of exacerbations with respect to prognosis, and makes the grouping more favorable for clinicians to make treatment decisions.[@b9-copd-13-3011] At the same time, some patients with COPD originally categorized as Groups C and D were reclassified into Groups A and B. Two previous studies on 2017 GOLD classification showed that the new grading system resulted in large changes in the demographic characteristics of patients with COPD distributed in the four categories, ie, A, B, C, and D.[@b10-copd-13-3011],[@b11-copd-13-3011] Two other studies arrived at similar conclusions, except for slightly different distributions among the groups.[@b12-copd-13-3011],[@b13-copd-13-3011] At the same time, a study by Marçoa et al indicated that patients in Group B of the new grading system had a higher risk of acute exacerbations than the old classification.[@b13-copd-13-3011] However, these studies mainly evaluated the new categories from the perspective of basic demographic characteristics and distribution changes. The effectiveness of the new categories on the overall assessment of the severity of COPD remains unknown.

In recent years, more and more clinical indicators have been used to assess the severity of COPD. In clinical practice, the comprehensive assessment of COPD using multiple parameters such as pulmonary function, symptoms, quality of life, nutritional status, respiratory muscle function, exercise capacity, emotional status, and other parameters could make up for the limitations of a single-indicator assessment and offer a more accurate way to evaluate disease severity. A previous work by our team showed that the comprehensive assessment approach had a good effect on the evaluation of pulmonary rehabilitation in patients with COPD.[@b14-copd-13-3011] Therefore, in the present study, we analyzed changes in characteristics brought about by the new A-B-C-D categories, used well-accepted and closely related indicators of disease severity to compare with the 2011 GOLD classification, and explored its role in comprehensive assessment.

Subjects and methods
====================

Subjects and study design
-------------------------

In this study, a cross-sectional survey was conducted by selecting patients with stable COPD at the Respiratory Medicine Clinic of Zhujiang Hospital of Southern Medical University from January 2013 to December 2016. Inclusion criteria were age ≥40 years; diagnosis of COPD according to pulmonary function tests, ie, FEV~1~/FVC\<0.70 after inhaling 400 µg of salbutamol aerosol, determined that there was a persistent airflow limitation. Patients with bronchial asthma, advanced tuberculosis, bronchiectasis, severe cardiovascular disease, and those who had an exacerbation within the prior 8 weeks were excluded. An exacerbation was defined as an acute worsening of respiratory symptoms that resulted in additional therapy (including short-acting bronchodilators, antibiotics, or oral steroids).[@b9-copd-13-3011] Frequent exacerbations were defined as ≥2 exacerbations in the previous year, or at least one hospital admission due to a COPD exacerbation.

The study was approved by the Ethics Committee of Zhujiang Hospital, Southern Medical University, and conformed to the Helsinki Affirmation. The purpose, significance, and potential benefits and risks of the study were presented to patients. All patients signed informed consent.

Pulmonary function tests were performed first, and the degree of airflow limitation was graded based on FEV~1~% predicted: GOLD grade 1, ≥80 FEV~1~% predicted; GOLD grade 2, 50--79 FEV~1~% predicted; GOLD grade 3, 30--49 FEV~1~% predicted; GOLD grade 4, \<30 FEV~1~% predicted. Subjects were also investigated by questionnaires, including the COPD Assessment Test (CAT)[@b15-copd-13-3011] and the Modified Medical Research Council Scale (mMRC).[@b16-copd-13-3011] The number of exacerbations in the previous year, CAT≥10, mMRC≥2, and whether there is frequent exacerbation were used as grouping thresholds. The mMRC classification was used when it was inconsistent with CAT score. According to the 2011 GOLD,[@b17-copd-13-3011] all subjects were divided into A~1~, B~1~, C~1~, and D~1~ categories, and redivided into A~2~, B~2~, C~2~, and D~2~ categories according to the 2017 GOLD.[@b1-copd-13-3011]

Data collection and comprehensive assessment
--------------------------------------------

Data collection for all COPD subjects was completed within 3 days of inclusion in the study. Data collected included demographic characteristics, smoking history, history of exacerbations, and other relevant comprehensive assessment parameters such as pulmonary function testing results, respiratory muscle strength, symptoms and quality of life, exercise capacity, nutritional status, and anxiety and depression. All relevant data were collected by experienced respiratory physicians.

Pulmonary function
------------------

Pulmonary function was measured by a spirometer (Pony FX229; Cosmed, Rome, Italy), which met the ATS guidelines.[@b18-copd-13-3011] The collected parameters of pulmonary function included FEV~1~, FVC, FEV~1~% predicted, and FEV~1~/FVC, and were all measured before and after a bronchodilator test. The bronchodilator test was performed 20 minutes after inhaling 400 µg of salbutamol aerosol. Patients were excluded if they used any bronchial inhalation drug 3 days prior to the pulmonary function testing. Before and after the testing, three curves that accorded to the standards were selected for analysis.

Respiratory muscle strength
---------------------------

Respiratory muscle function was determined by maximal inspiratory pressure (PImax) and maximal expiratory pressure (PEmax). A digital manometer (AZ-8205; AZ Instruments, Taichung City, Taiwan) was used. Quality control was conducted according to the American Thoracic Society and the European Respiratory Society standardization protocols.[@b19-copd-13-3011] The three largest measurements were selected for analysis. The lower limit of the normal value for PImax was 75 cm H~2~O in males, and 50 cm H~2~O in females. The lower limit of the normal value for PEmax was 100 cm H~2~O in males, and 80 cm H~2~O in females.[@b20-copd-13-3011]

Symptom and quality of life
---------------------------

Severity of symptoms was evaluated by CAT scores and mMRC grades. Quality of life was evaluated using the St George's Respiratory Questionnaire (SGRQ).[@b21-copd-13-3011]

Exercise capacity
-----------------

Exercise capacity was determined by a 6-minute walking distance (6MWD), according to the American Thoracic Society guidelines.[@b22-copd-13-3011] During the test, oxygen saturation and heart rate were monitored by pulse oximetry (8A; Jiaxing-Kanghe, Beijing, China). The whole process was under the supervision of an experienced respiratory physician to ensure that the oxygen saturation was maintained at above 90%. The maximum value measured over 2 days was used for analysis.

Nutritional status
------------------

Nutritional status was evaluated by body mass index (BMI) and fat-free body mass index (FFMI), as described in prior research.[@b23-copd-13-3011],[@b24-copd-13-3011] BMI and FFMI were measured by multifrequency and 8-spot electrodes (Inbody720; Biospace, Seoul, Korea) at the Department of Endocrinology of Zhujiang Hospital of Southern Medical University. Measurements were performed twice, and the average was used for analysis. BMI=body mass (BM)/(height)^2^ (m^2^). FFMI=fat-free body mass (FFM)/(height)^2^ (m^2^).

Depression and anxiety
----------------------

Depression and anxiety were assessed by the Hospital Anxiety and Depression Scale (HADS).[@b25-copd-13-3011] The scale contains seven questions about depression and seven questions about anxiety. The HADS was administered by experienced physicians.

Statistical analysis
--------------------

Statistical analyses were performed using SPSS 20 (IBM Corporation, Armonk, NY, USA). Results were presented as the mean±SD for continuous variables, and categorical data were presented as numbers and percentages. Differences between two groups in the same category were compared by the independent samples *t*-test. The marginal homogeneity test was used to assess the distribution changes between the 2011 GOLD and the 2017 GOLD. The coherence of the two grouping methods was expressed by Cohen's K coefficient.[@b13-copd-13-3011] Group A served as the reference to the other three categories in the comprehensive assessment using multiple linear regression (patient characteristics were outcome variables, and the other three categories were dummy independent variables). A value of *P*\<0.05 was considered statistically significant.

Results
=======

A total of 755 patients were initially enrolled in this study, of whom 124 did not meet the COPD criteria. Thus, 631 patients were ultimately included in the analysis ([Figure 1](#f1-copd-13-3011){ref-type="fig"}). Baseline patient characteristics are shown in [Table 1](#t1-copd-13-3011){ref-type="table"}. The mean age of all subjects was 67.52±10.55 years, with males accounting for 81.1% of the population. The mean smoking index of all patients was 26.12±27.62; 31.2% were never-smokers, 36.5% were former smokers, and 32.3% were current smokers. According to the 2011 GOLD, 17.9% (n=113) of the total population were in Group A~1~, 12.7% (n=80) were in Group B~1~, 24.4% (n=154) were in Group C~1~, and 45.0% (n=284) were in Group D~1~. According to the 2017 GOLD, 28.0% (n=177) of the population were in Group A~2~, 24.9% (n=157) were in Group B~2~, 14.3% (n=90) were in Group C~2~, and 32.8% (n=207) were in Group D~2~.

2017 GOLD grouping brings changes
---------------------------------

In order to demonstrate the distributional changes that occurred as a result of changes in the grading system, the distributions of all patients according to the 2011 GOLD and 2017 GOLD are presented in [Figure 2](#f2-copd-13-3011){ref-type="fig"}. According to the new grouping criteria, 64 patients were reclassified into Group A~2~ from Group C~1~, accounting for 41.6% of the original total. Seventy-seven patients were reclassified into Group B~2~ from Group D~1~, accounting for 27.1% of the original total. In summary, a total of 141 patients were reclassified to the new group. As shown in [Figure 2](#f2-copd-13-3011){ref-type="fig"}, the marginal homogeneity test demonstrated the difference in the distribution of patients in the 2011 GOLD and 2017 GOLD was statistically significant (*χ*^2^=11.874, *P*\<0.001). Cohen's kappa coefficient was 0.6963, indicating the two classification systems have some degree of consistency (*Z*=31.14, *P*\<0.001; [Table 2](#t2-copd-13-3011){ref-type="table"}).

The differences of comprehensive assessment parameters between two groups in the same category in the 2011 GOLD and 2017 GOLD are shown in [Table 3](#t3-copd-13-3011){ref-type="table"}. In category A, patients in Group A~2~ had significantly lower FEV~1~, FVC, FEV~1~% predicted, and FEV~1~/FVC (*P*\<0.001), while mMRC (*P*=0.045) and body mass index, airflow obstruction, dyspnea, and exercise capacity index (BODE index; *P*\<0.001) were higher than in the old group. In category B, patients in Group B~2~ had lower FEV~1~, FVC, FEV~1~% predicted, FEV~1~/FVC, 6MWD, PImax, and PEmax (*P*\<0.001), while BODE was higher than in the previous group (*P*\<0.001). In category D, none of the parameters changed significantly.

2011 GOLD and 2017 GOLD grouping in the comprehensive assessment of the characteristics
---------------------------------------------------------------------------------------

To further show the differences between groups in the new grading system, after adjusting for age, sex, and smoking index, the characteristics of the comprehensive evaluation of each group were compared and the results are presented in [Tables 4](#t4-copd-13-3011){ref-type="table"} and [5](#t5-copd-13-3011){ref-type="table"}. In the 2017 GOLD, patients in Group D~2~ had significantly lower FEV~1~, FVC, FEV~1~% predicted, 6MWD, PImax, PEmax, BMI, and FFMI, and higher mMRC, CAT, SGRQ, BODE, and HADS scores than patients in Group A~2~ (*P*\<0.001). Similar results were observed for patients in Group B~2~, except for no significant difference in BMI (*P*=0.158). The differences between Groups A~2~ and C~2~ were relatively small.

Discussion
==========

The results of this study showed that the new A-B-C-D grouping method based on the 2017 GOLD underwent tremendous changes in terms of clinical features and comprehensive evaluation compared with the 2011 GOLD. Almost half of the patients originally located in Group C~1~ based on the 2011 GOLD were reclassified into Group A~2~. Among the patients originally in Group D~1~ in the 2011 GOLD, nearly 30% were reclassified into Group B~2~. In addition, patients in Groups A~2~ and B~2~ had significantly worse lung function compared with the old group, especially Group B~2~ in which patients also had worse exercise performance and respiratory muscle strength. In the 2017 GOLD, when lung function was no longer a basis for grouping, patients in each group had significant differences in disease severity. Compared with patients in Groups A~2~ and C~2~, those in Groups B~2~ and D~2~ had worse comprehensive assessment outcomes.

Obviously, the change of assessment method was the main reason for the above changes. All of the patients who were reclassified into a lower group were at higher risk in the old grading system because they all had poorer lung function, instead of more frequent exacerbations. Tudoric et al showed that in the revised A-B-C-D classification, about half of the patients in Group C of the 2011 GOLD were reclassified into Group A, and more than one-third of those formerly in Group D were reclassified into Group B according to the 2017 GOLD.[@b10-copd-13-3011] Similar conclusions were arrived at in a study by Sun et al.[@b11-copd-13-3011] But two other studies showed that more than half of the patients in both Groups C and D were reclassified into low-risk groups.[@b12-copd-13-3011],[@b13-copd-13-3011] This was slightly different from the change in distribution found in this study, with the difference mainly due to the lower proportion of people being redistributed into Group B. Similar to Sun et al,[@b11-copd-13-3011] but different from the other studies, was that in the 2011 evaluation method, Groups C and D had a larger number of subjects, while Groups A and B were relatively smaller.

This matches the real situation of COPD in China because most patients tend to go to the hospital only when their lung function is deteriorating and symptoms have become more severe. This study also showed that there was a low degree of consistency between the newly revised evaluation method and the previous one, resulting in large differences in the distribution between groups and in clinical characteristics.

At the same time, we should also recognize that the existing assessment model is still relatively simple. COPD is a chronic inflammatory disease. In addition to impaired pulmonary function and respiratory symptoms, COPD produces a series of extrapulmonary manifestations such as decreased exercise ability, malnutrition, osteoporosis, anxiety, and depression. A comprehensive assessment of as many aspects as possible could offer a more accurate evaluation of the severity of COPD. For example, Celli et al used the BODE index consisting of four indicators to predict the long-term prognosis of patients with COPD, and found it superior to FEV~1~ alone.[@b26-copd-13-3011] Previous research by our team also demonstrated that the comprehensive assessment had greater power for the evaluation of pulmonary rehabilitation in patients with COPD.[@b14-copd-13-3011] Our study found that Groups C and D barely changed when evaluating the differences between the 2011 and 2017 GOLD by comprehensive assessment. Especially, there were no significant differences in the clinical characteristics of Group D. However, changes were significant in both Groups A and B, with patients in the new group significantly worse in terms of lung function and BODE index than the original group. Although lung function no longer serves as a basis for grouping in the current evaluation model, the ECLIPSE study targeting the 2011 classification also recommended more methods for assessing COPD than FEV~1~ alone.[@b27-copd-13-3011] However, the 2017 GOLD pointed out that lung function was still very important in disease diagnosis, outcome prediction, and evaluating treatment options, as are symptoms and acute exacerbations.[@b9-copd-13-3011] The results of this study also indicated that lung function may still play a significant role in the assessment of disease severity, especially because lung function may have a more pronounced effect on respiratory muscle function, exercise capacity, and BODE index in Group B. As patients in Group C and D had more severe exacerbations, the study showed that acute exacerbations have an adverse effect on a patient's health status, hospitalization rate, and prognosis.[@b28-copd-13-3011],[@b29-copd-13-3011] The impact of lung function changes on this part of the subjects may be relatively small, so the new group and the old group did not produce more obvious changes in many perspectives.

In the 2011 assessment model, it was reported that the incidence of cardiovascular and metabolic diseases significantly increased with increasing A-B-C-D group.[@b30-copd-13-3011] But, as previously described,[@b5-copd-13-3011]--[@b7-copd-13-3011] compared with a single lung function classification, this assessment model did not show any significant advantage in predicting patient outcomes. A study had even shown that this evaluation system was not as good as the BODE index in predicting the long-term survival of patients.[@b31-copd-13-3011] Our results also showed that while the 2017 GOLD simply excluded pulmonary function from grouping criteria, the new A-B-C-D groups had distinct clinical features compared with the former groups. Groups A~2~ and C~2~ were significantly better than Groups B~2~ and D~2~ with respect to lung function, symptoms, exercise capacity, respiratory muscle function, and other indicators, rather than the original linear distribution. Research by Lange et al showed that in the 2011 A-B-C-D evaluation system, long-term survival was lower in patients who had more severe dyspnea and were in Group B than in patients in Group C.[@b32-copd-13-3011] The ECLIPSE study also found that in the 2011 assessment model, patients in Groups B and C had more variability, yet similar clinical outcomes.[@b27-copd-13-3011] The results of this study may be because the new assessment model is based only on symptom evaluation and the number of exacerbations as a grouping basis, making the characteristics of different groups more pronounced. Overall, it appears that in the comprehensive evaluation of COPD, symptom assessment may play an extremely important role, and may be one of the most significant factors that determines the long-term outcome of patients. At the same time, only inhaled glucocorticoids are recommended for patients in Groups C and D, and not for those in Group B. However, if the severity of illness in Group B is worse than that in Group C, the rationality of this recommendation should be examined.

In summary, the results of this study suggested that in the revised evaluation method, patients in Groups B and D may have worse disease severity, and the long-term prognosis may be less optimistic, suggesting that clinicians should pay more attention to the condition of patients in Group B. Of course, all these results remain to be confirmed by further explorations.

There are some limitations to the current study. First, we evaluated the two assessment systems by cross-sectional data, rather than long-term dynamic observations and assessment of the corresponding prognostic indices. In addition, data for this study came mainly from hospitals, and the patient distributions were somewhat different from previous large-scale cross-sectional studies, and also did not fully reflect the distribution of COPD in the general population.

Conclusion
==========

We found that compared with the 2011 GOLD, the 2017 GOLD classified more patients to Groups A and B, with significantly worse lung function and higher BODE index in both groups. At the same time, in the 2017 GOLD, patients in each group were not linearly distributed in disease severity, and the disease severity in Groups B and D was possibly more serious. However, the effectiveness of the new grading system in predicting patient prognosis and guiding the use of drugs remains to be further refined in future studies.
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###### 

Patient characteristics at baseline

  ------------------------------------- ----------------
  Age (years)                           67.52±10.55
  Male subjects, n (%)                  512 (81.1%)
  BMI (kg/m^2^)                         22.17±3.81
  Non-hospitalization, n (%)            389 (61.6%)
  Smoking status                        
   Smoking index (pack-years)           26.12±27.62
   Never-smoker, n (%)                  197 (31.2%)
   Former smoker, n (%)                 230 (36.5%)
   Current smoker, n (%)                204 (32.3%)
  Pharmacological therapy               
   No treatment, n (%)                  132 (20.9%)
   Bronchodilators, n (%)               182 (28.8%)
   ICS, n (%)                           55 (8.7%)
   Bronchodilators + ICS, n (%)         262 (41.5%)
  A-B-C-D group                         
   2011 GOLD, n (A~1~/B~1~/C~1~/D~1~)   113/80/154/284
   2017 GOLD, n (A~2~/B~2~/C~2~/D~2~)   177/157/90/207
  ------------------------------------- ----------------

**Notes:** Continuous variables are presented as the mean±SD; categorical variables are presented as numbers and percentages unless stated otherwise. Groups A~1~--D~1~ are categories according to the 2011 GOLD; Groups A~2~--D~2~ are categories according to the 2017 GOLD.

**Abbreviations:** BMI, body mass index; GOLD, Global Initiative for Chronic Obstructive Lung Disease; ICS, inhaled corticosteroid.

###### 

Coherence between 2011 GOLD and 2017 GOLD classifications

                           2011 GOLD                     
  ------------------------ ----------- -------- -------- ---------
  2017 GOLD                                              
   A~2~ (n=177)            **113**     0        64       0
   B~2~ (n=157)            0           **80**   0        77
   C~2~ (n=90)             0           0        **90**   0
   D~2~ (n=207)            0           0        0        **207**
  Cohen's kappa = 0.6963                                 

**Notes:** Groups A~1~--D~1~ are categories according to the 2011 GOLD; Groups A~2~--D~2~ are categories according to the 2017 GOLD. The bold numbers indicate the consistency of distribution between the 2011 GOLD and the 2017 GOLD. The underlined numbers indicate the disagreement of distribution between the 2011 GOLD and the 2017 GOLD.

**Abbreviation:** GOLD, Global Initiative for Chronic Obstructive Lung Disease.

###### 

Comparison of comprehensive assessment between the two groups in the same category

                               Group A        Group B                                                   Group C        Group D                                                                                                                                             
  ---------------------------- -------------- --------------------------------------------------------- -------------- ---------------------------------------------------------- -------------- --------------------------------------------------------- --------------- ---------------
  Age (years)                  66.34±9.02     65.32±9.29                                                65.55±13.41    66.75±11.70                                                66.31±9.68     68.29±9.33                                                69.20±10.46     69.65±10.77
  Male/female                  (91/22)        (141/36)                                                  (62/18)        (133/24)                                                   (124/30)       (74/16)                                                   (235/49)        (164/43)
  Smoking index (pack-years)   22.21±27.89    23.07±26.20                                               19.98±21.15    27.58±26.90[a](#tfn6-copd-13-3011){ref-type="table-fn"}    24.28±21.75    24.07±20.91                                               30.41±31.19     28.52±31.51
  FEV~1~ (L)                   1.81±0.49      1.53±0.56[b](#tfn7-copd-13-3011){ref-type="table-fn"}     1.59±0.43      1.26±0.49[b](#tfn7-copd-13-3011){ref-type="table-fn"}      1.23±0.45      1.36±0.49[a](#tfn6-copd-13-3011){ref-type="table-fn"}     1.04±0.45       1.08±0.50
  FEV~1~ % pred (%)            73.07±14.76    60.92±20.45[b](#tfn7-copd-13-3011){ref-type="table-fn"}   67.33±10.49    51.88±18.42[b](#tfn7-copd-13-3011){ref-type="table-fn"}    50.82±17.12    58.89±17.63[b](#tfn7-copd-13-3011){ref-type="table-fn"}   44.20±18.47     47.32±20.17
  FVC (L)                      3.06±0.74      2.73±0.83[b](#tfn7-copd-13-3011){ref-type="table-fn"}     2.76±0.79      2.39±0.76[b](#tfn7-copd-13-3011){ref-type="table-fn"}      2.37±0.72      2.53±0.74                                                 2.20±0.75       2.27±0.81
  FEV~1~/FVC (%)               60.45±9.39     56.54±10.46[b](#tfn7-copd-13-3011){ref-type="table-fn"}   59.20±8.62     52.94±11.09[b](#tfn7-copd-13-3011){ref-type="table-fn"}    52.82±10.50    55.08±11.20                                               47.43±12.27     47.80±13.15
  mMRC                         0.48±0.50      0.60±0.49[a](#tfn6-copd-13-3011){ref-type="table-fn"}     2.30±0.56      2.42±0.65                                                  0.79±0.44      0.78±0.47                                                 2.74±0.78       2.81±0.79
  CAT                          6.93±4.00      7.47±4.00                                                 17.45±5.53     17.46±5.84                                                 8.92±3.77      9.27±3.70                                                 20.51±7.04      21.65±7.02
  SGRQ                         15.14±7.50     16.81±8.02                                                28.53±11.14    30.07±11.79                                                19.46±8.24     19.26±8.37                                                35.25±13.05     36.58±13.10
  6MWD (m)                     512.35±69.28   500.71±68.64                                              437.25±93.57   402.01±99.95[b](#tfn7-copd-13-3011){ref-type="table-fn"}   466.62±75.61   457.00±82.47                                              360.10±116.92   358.12±124.67
  PImax (cm H~2~O)             69.77±18.81    66.86±19.30                                               62.22±17.95    55.70±18.11[b](#tfn7-copd-13-3011){ref-type="table-fn"}    59.91±17.67    58.62±16.46                                               51.19±16.42     52.03±16.63
  PEmax (cm H~2~O)             80.43±24.97    76.42±27.88                                               68.33±18.58    61.25±17.68[b](#tfn7-copd-13-3011){ref-type="table-fn"}    66.59±25.66    64.64±20.67                                               58.09±19.33     59.65±20.97
  FFMI (kg/m^2^)               17.18±1.88     17.22±1.91                                                16.56±2.46     16.17±2.34                                                 16.81±1.82     16.47±1.62                                                15.68±2.19      15.65±2.21
  BMI (kg/m^2^)                23.14±2.52     23.11±2.84                                                23.15±3.82     22.42±4.24                                                 22.65±3.57     22.36±3.71                                                21.25±4.14      21.09±3.98
  BODE                         0.61±0.73      1.37±1.25[b](#tfn7-copd-13-3011){ref-type="table-fn"}     2.13±1.17      3.47±1.83[b](#tfn7-copd-13-3011){ref-type="table-fn"}      2.06±1.37      1.60±1.52[a](#tfn6-copd-13-3011){ref-type="table-fn"}     4.66±1.97       4.58±2.18
  HADS                         2.63±1.43      2.68±1.45                                                 3.50±1.70      3.69±1.58                                                  3.75±1.55      4.44±1.17[b](#tfn7-copd-13-3011){ref-type="table-fn"}     3.83±1.40       3.81±1.40
  HADS depression              1.46±1.14      1.60±1.22                                                 1.80±1.22      1.90±1.25                                                  2.04±1.16      2.17±1.02                                                 1.95±1.13       1.93±1.08
  HADS anxiety                 1.22±1.05      1.14±0.99                                                 1.70±1.11      1.80±1.11                                                  1.76±1.17      2.30±1.07[b](#tfn7-copd-13-3011){ref-type="table-fn"}     1.89±1.15       1.89±1.17

**Notes:** Continuous variables are presented as the mean±SD; categorical variables are presented as numbers and percentages unless stated otherwise. Groups A~1~--D~1~ are categories according to the 2011 GOLD; Groups A~2~--D~2~ are categories according to the 2017 GOLD.

Compared with the 2011 GOLD, *P*\<0.05;

Compared with the 2011 GOLD, *P*\<0.001.

**Abbreviations:** 6MWD, 6-minute walking distance; % pred, percent predicted; BMI, body mass index; BODE, body mass index, airflow obstruction, dyspnea, and exercise capacity index; CAT, COPD Assessment Test; FFMI, fat-free mass index; HADS, Hospital Anxiety and Depression Scale; mMRC, Modified Medical Research Council Scale; PEmax, maximal expiratory pressure; PImax, maximal inspiratory pressure; SGRQ, St George's Respiratory Questionnaire.

###### 

Comparison of comprehensive assessment between Group A and the other three categories in the 2011 GOLD

                      A~1~ (n=113)   B~1~ (n=80)                                                                 C~1~ (n=154)                                                                 D~1~ (n=284)
  ------------------- -------------- --------------------------------------------------------------------------- ---------------------------------------------------------------------------- ----------------------------------------------------------------------------
  FEV~1~ (L)          0.00 (Ref)     −**0.22** (−0.35 to −0.09)[b](#tfn11-copd-13-3011){ref-type="table-fn"}     −**0.58** (−0.69 to −0.47)[b](#tfn11-copd-13-3011){ref-type="table-fn"}      −**0.75** (−0.85 to −0.65)[b](#tfn11-copd-13-3011){ref-type="table-fn"}
  FEV~1~ % pred (%)   0.00 (Ref)     −**6.14** (−10.72 to −1.57)[a](#tfn10-copd-13-3011){ref-type="table-fn"}    −**22.15** (−26.03 to −18.28)[b](#tfn11-copd-13-3011){ref-type="table-fn"}   −**29.08** (−32.59 to −25.56)[b](#tfn11-copd-13-3011){ref-type="table-fn"}
  FVC~1~ (L)          0.00 (Ref)     −**0.28** (−0.48 to −0.08)[a](#tfn10-copd-13-3011){ref-type="table-fn"}     −**0.69** (−0.86 to −0.52)[b](#tfn11-copd-13-3011){ref-type="table-fn"}      −**0.83** (−0.99 to −0.68)[b](#tfn11-copd-13-3011){ref-type="table-fn"}
  FEV~1~/FVC (%)      0.00 (Ref)     −1.56 (−4.61 to 1.49)                                                       −**7.54** (−10.12 to −4.95)[b](#tfn11-copd-13-3011){ref-type="table-fn"}     −**12.81** (−15.15 to −10.46)[b](#tfn11-copd-13-3011){ref-type="table-fn"}
  mMRC                0.00 (Ref)     **1.83** (1.64 to 2.01)[b](#tfn11-copd-13-3011){ref-type="table-fn"}        **0.31** (0.16 to 0.47)[b](#tfn11-copd-13-3011){ref-type="table-fn"}         **2.26** (2.12 to 2.40)[b](#tfn11-copd-13-3011){ref-type="table-fn"}
  CAT                 0.00 (Ref)     **10.53** (8.90 to 12.15)[b](#tfn11-copd-13-3011){ref-type="table-fn"}      **1.93** (0.55 to 3.31)[a](#tfn10-copd-13-3011){ref-type="table-fn"}         **13.32** (12.07 to 14.57)[b](#tfn11-copd-13-3011){ref-type="table-fn"}
  SGRQ                0.00 (Ref)     **13.22** (10.11 to 16.33)[b](#tfn11-copd-13-3011){ref-type="table-fn"}     **4.24** (1.61 to 6.88)[a](#tfn10-copd-13-3011){ref-type="table-fn"}         **20.09** (17.70 to 22.48)[b](#tfn11-copd-13-3011){ref-type="table-fn"}
  6MWD (100 m)        0.00 (Ref)     −**0.77** (−1.04 to −0.51)[b](#tfn11-copd-13-3011){ref-type="table-fn"}     −**0.46** (−0.68 to −0.23)[b](#tfn11-copd-13-3011){ref-type="table-fn"}      −**1.43** (−1.64 to −1.23)[b](#tfn11-copd-13-3011){ref-type="table-fn"}
  PImax (cm H~2~O)    0.00 (Ref)     −**7.72** (−12.46 to −2.98)[a](#tfn10-copd-13-3011){ref-type="table-fn"}    −**9.76** (−13.78 to −5.75)[b](#tfn11-copd-13-3011){ref-type="table-fn"}     −**16.92** (−20.56 to −13.28)[b](#tfn11-copd-13-3011){ref-type="table-fn"}
  PEmax (cm H~2~O)    0.00 (Ref)     −**12.55** (−18.62 to −6.47)[b](#tfn11-copd-13-3011){ref-type="table-fn"}   −**13.78** (−18.93 to −8.63)[b](#tfn11-copd-13-3011){ref-type="table-fn"}    −**20.39** (−25.06 to −15.72)[b](#tfn11-copd-13-3011){ref-type="table-fn"}
  FFMI (kg/m^2^)      0.00 (Ref)     −**0.58** (−1.17 to −0.00)[a](#tfn10-copd-13-3011){ref-type="table-fn"}     −0.36 (−0.86 to 0.13)                                                        −**1.43** (−1.88 to −0.98)[a](#tfn10-copd-13-3011){ref-type="table-fn"}
  BMI (kg/m^2^)       0.00 (Ref)     −0.09 (−1.14 to 0.97)                                                       −0.47 (−1.37 to 0.43)                                                        −**1.69** (−2.50 to −0.88)[a](#tfn10-copd-13-3011){ref-type="table-fn"}
  BODE                0.00 (Ref)     **1.55** (1.11 to 2.00)[b](#tfn11-copd-13-3011){ref-type="table-fn"}        **1.45** (1.07 to 1.83)[b](#tfn11-copd-13-3011){ref-type="table-fn"}         **4.01** (3.67 to 4.35)[b](#tfn11-copd-13-3011){ref-type="table-fn"}
  HADS                0.00 (Ref)     **0.87** (0.45 to 1.30)[b](#tfn11-copd-13-3011){ref-type="table-fn"}        **1.12** (0.76 to 1.48)[b](#tfn11-copd-13-3011){ref-type="table-fn"}         **1.15** (0.83 to 1.48)[b](#tfn11-copd-13-3011){ref-type="table-fn"}
  HADS depression     0.00 (Ref)     **0.35** (0.04 to 0.68)[a](#tfn10-copd-13-3011){ref-type="table-fn"}        0**.58** (0.30 to 0.86)[b](#tfn11-copd-13-3011){ref-type="table-fn"}         **0.46** (0.21 to 0.72)[b](#tfn11-copd-13-3011){ref-type="table-fn"}
  HADS anxiety        0.00 (Ref)     **0.47** (0.15 to 0.79)[a](#tfn10-copd-13-3011){ref-type="table-fn"}        **0.54** (0.26 to 0.81)[b](#tfn11-copd-13-3011){ref-type="table-fn"}         **0.66** (0.41 to 0.91)[b](#tfn11-copd-13-3011){ref-type="table-fn"}

**Notes:** Groups A~1~--D~1~ are categories according to the 2011 GOLD. Data are presented as regression coefficient (95% CI) unless stated otherwise. Bold numbers indicate statistical significance when Group A~1~, which was set as the reference (Ref), was compared with the other three categories (as dummy variables) after adjusting for age, sex, and smoking index.

Compared with Group A~1~, *P*\<0.05;

Compared with Group A~1~, *P*\<0.001.

**Abbreviations:** 6MWD, 6-minute walking distance; % pred, percent predicted; BMI, body mass index; BODE, body mass index, airflow obstruction, dyspnea, and exercise capacity index; CAT, COPD Assessment Test; FFMI, fat-free mass index; GOLD, Global Initiative for Chronic Obstructive Lung Disease; HADS, Hospital Anxiety and Depression Scale; mMRC, Modified Medical Research Council Scale; PEmax, maximal expiratory pressure; PImax, maximal inspiratory pressure; SGRQ, St George's Respiratory Questionnaire.

###### 

Comparison of comprehensive assessment between Group A and the other three categories in the 2017 GOLD

                      A~2~ (n=177)   B~2~ (n=157)                                                                C~2~ (n=90)                                                                 D~2~ (n=207)
  ------------------- -------------- --------------------------------------------------------------------------- --------------------------------------------------------------------------- ----------------------------------------------------------------------------
  FEV~1~ (L)          0.00 (Ref)     −**0.26** (−0.37 to −0.15)[b](#tfn15-copd-13-3011){ref-type="table-fn"}     −**0.14** (−0.27 to −0.01)[a](#tfn14-copd-13-3011){ref-type="table-fn"}     −**0.40** (−0.51 to −0.30)[b](#tfn15-copd-13-3011){ref-type="table-fn"}
  FEV~1~ % pred (%)   0.00 (Ref)     −**8.78** (−12.83 to −4.73)[b](#tfn15-copd-13-3011){ref-type="table-fn"}    −2.40 (−7.19 to 2.38)                                                       −**14.14** (−17.97 to −10.31)[b](#tfn15-copd-13-3011){ref-type="table-fn"}
  FVC (L)             0.00 (Ref)     −**0.33** (−0.49 to −0.16)[b](#tfn15-copd-13-3011){ref-type="table-fn"}     −0.16 (−0.35 to 0.03)                                                       −**0.39** (−0.54 to −0.23)[b](#tfn15-copd-13-3011){ref-type="table-fn"}
  FEV~1~/FVC (%)      0.00 (Ref)     −**3.32** (−5.75 to −0.90)[a](#tfn14-copd-13-3011){ref-type="table-fn"}     −1.50 (−4.37 to 1.37)                                                       −**8.74** (−11.04 to −6.45)[b](#tfn15-copd-13-3011){ref-type="table-fn"}
  mMRC                0.00 (Ref)     **1.82** (1.68 to 1.96)[b](#tfn15-copd-13-3011){ref-type="table-fn"}        **0.18** (0.02 to 0.34)[a](#tfn14-copd-13-3011){ref-type="table-fn"}        **2.21** (2.08 to 2.34)[b](#tfn15-copd-13-3011){ref-type="table-fn"}
  CAT                 0.00 (Ref)     **9.86** (8.67 to 11.05)[b](#tfn15-copd-13-3011){ref-type="table-fn"}       **1.77** (0.37 to 3.18)[a](#tfn14-copd-13-3011){ref-type="table-fn"}        **13.97** (12.85 to 15.10)[b](#tfn15-copd-13-3011){ref-type="table-fn"}
  SGRQ                0.00 (Ref)     **13.26** (10.92 to 15.59)[b](#tfn15-copd-13-3011){ref-type="table-fn"}     2.73 (−0.03 to 5.49)                                                        **19.90** (17.70 to 22.11)[b](#tfn15-copd-13-3011){ref-type="table-fn"}
  6MWD (100 m)        0.00 (Ref)     −**0.94** (−1.14 to −0.73)[b](#tfn15-copd-13-3011){ref-type="table-fn"}     −**0.35** (−0.60 to −0.11)[a](#tfn14-copd-13-3011){ref-type="table-fn"}     −**1.29** (−1.49 to −1.10)[b](#tfn15-copd-13-3011){ref-type="table-fn"}
  PImax (cm H~2~O)    0.00 (Ref)     −**10.33** (−13.97 to −6.68)[b](#tfn15-copd-13-3011){ref-type="table-fn"}   −**6.89** (−11.20 to −2.57)[a](#tfn14-copd-13-3011){ref-type="table-fn"}    −**12.42** (−15.87 to −8.97)[b](#tfn15-copd-13-3011){ref-type="table-fn"}
  PEmax (cm H~2~O)    0.00 (Ref)     −**14.14** (−18.79 to −9.49)[b](#tfn15-copd-13-3011){ref-type="table-fn"}   −**10.06** (−15.56 to −4.57)[b](#tfn15-copd-13-3011){ref-type="table-fn"}   −**13.98** (−18.38 to −9.59)[b](#tfn15-copd-13-3011){ref-type="table-fn"}
  FFMI (kg/m^2^)      0.00 (Ref)     −**1.03** (−1.47 to −0.59)[b](#tfn15-copd-13-3011){ref-type="table-fn"}     −**0.72** (−1.23 to −0.20)[a](#tfn14-copd-13-3011){ref-type="table-fn"}     −**1.45** (−1.87 to −1.04)[b](#tfn15-copd-13-3011){ref-type="table-fn"}
  BMI (kg/m^2^)       0.00 (Ref)     −0.57 (−1.37 to 0.22)                                                       −0.63 (−1.57 to 0.31)                                                       −**1.80** (−2.56 to −1.05)[b](#tfn15-copd-13-3011){ref-type="table-fn"}
  BODE                0.00 (Ref)     **2.05** (1.67 to 2.43)[b](#tfn15-copd-13-3011){ref-type="table-fn"}        0.19 (−0.26 to 0.63)                                                        **3.15** (2.79 to 3.51)[b](#tfn15-copd-13-3011){ref-type="table-fn"}
  HADS                0.00 (Ref)     **0.99** (0.68 to 1.30)[b](#tfn15-copd-13-3011){ref-type="table-fn"}        **1.74** (1.38 to 2.10)[b](#tfn15-copd-13-3011){ref-type="table-fn"}        **1.07** (0.78 to 1.36)[b](#tfn15-copd-13-3011){ref-type="table-fn"}
  HADS depression     0.00 (Ref)     **0.28** (0.03 to 0.53)[a](#tfn14-copd-13-3011){ref-type="table-fn"}        **0.56** (0.27 to 0.86)[b](#tfn15-copd-13-3011){ref-type="table-fn"}        **0.30** (0.07 to 0.54)[a](#tfn14-copd-13-3011){ref-type="table-fn"}
  HADS anxiety        0.00 (Ref)     **0.65** (0.42 to 0.89)[b](#tfn15-copd-13-3011){ref-type="table-fn"}        **1.14** (0.87 to 1.42)[b](#tfn15-copd-13-3011){ref-type="table-fn"}        **0.73** (0.50 to 0.95)[b](#tfn15-copd-13-3011){ref-type="table-fn"}

**Notes:** Groups A~2~--D~2~ are categories according to the 2017 GOLD. Data are presented as regression coefficient (95% CI) unless stated otherwise. Bold numbers indicate statistical significance when Group A~2~, which was set as the reference (Ref), was compared with the other three categories (as dummy variables) after adjusting for age, sex, and smoking index.

Compared with Group A~2~, *P*\<0.05;

Compared with Group A~2~, *P*\<0.001.

**Abbreviations:** % pred, percent predicted; 6MWD, 6-minute walking distance; BMI, body mass index; BODE, body mass index, airflow obstruction, dyspnea, and exercise capacity index; CAT, COPD Assessment Test; FFMI, fat-free mass index; GOLD, Global Initiative for Chronic Obstructive Lung Disease; HADS, Hospital Anxiety and Depression Scale; mMRC, Modified Medical Research Council Scale; PEmax, maximal expiratory pressure; PImax, maximal inspiratory pressure; SGRQ, St George's Respiratory Questionnaire.
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